Singapore’s Health Sciences Authority has approved clinical trials for a coronavirus vaccine candidate being developed by Arcturus Therapeutics and Duke-NUS Medical school.
Arcturus, a San Diego, California-based biopharmaceutical company, in partnership with Singapore’s Duke-NUS said they will begin human dosing tests as soon as possible.
In a joint statement, the company and medical school said the volunteer study would include up to 108 adults and would examine several dose levels.
Ahead of Arcturus and Duke-NUS’ announcement, there were more than 140 candidate vaccines in pre-clinical evaluation and 24 in clinical evaluation, according to the World Health Organization.
In its preclinical